Search results
Results from the WOW.Com Content Network
The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy ...
From injectables to side effects to PrEP, our annual Treatment Guide will answer all your questions about the treatment and prevention of HIV. Our 2022 HIV Treatment Guide is Here! Skip to main ...
Ritonavir, sold under the brand name Norvir, is an antiretroviral medication used along with other medications to treat HIV/AIDS. [4] [5] [8] This combination treatment is known as highly active antiretroviral therapy (HAART). [8]
The abbreviation PrEP now typically refers to pre-exposure prophylaxis for HIV prevention, the use of antiviral drugs as a strategy for the prevention of HIV/AIDS. [2] PrEP is one of a number of HIV prevention strategies for people who are HIV negative but who have a higher risk of acquiring HIV, including sexually active adults at increased risk of contracting HIV, people who engage in ...
A few similar medications followed over the next few years, but the fast-mutating virus found ways around them. Early treatments also required multiple daily pills and often caused harsh side effects.
(Reuters) -Gilead Sciences said on Thursday a late-stage study showed its long-acting injectable drug was more effective in preventing HIV infection in women compared to its existing daily pill ...
These three drugs work in combination to target the HIV reverse transcriptase protein in three ways, which reduces the virus's capacity to mutate. [5] In combination studies there were synergistic antiviral effects observed between emtricitabine and efavirenz, efavirenz and tenofovir, and emtricitabine and tenofovir. [5]
Truvada was previously only approved by the U.S. Food and Drug Administration (FDA) to treat HIV in those already infected. In 2012, the FDA approved the drug for use as pre-exposure prophylaxis (PrEP), based on growing evidence that the drug was safe and effective at preventing HIV in populations at increased risk of infection. [41]